677 related articles for article (PubMed ID: 9564833)
1. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
[TBL] [Abstract][Full Text] [Related]
2. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
3. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
Gruszka A; Ren SG; Dong J; Culler MD; Melmed S
Endocrinology; 2007 Dec; 148(12):6107-14. PubMed ID: 17656461
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyridine-sensitive calcium channel activity related to prolactin, growth hormone, and luteinizing hormone release from anterior pituitary cells in culture: interactions with somatostatin, dopamine, and estrogens.
Drouva SV; Rerat E; Bihoreau C; Laplante E; Rasolonjanahary R; Clauser H; Kordon C
Endocrinology; 1988 Dec; 123(6):2762-73. PubMed ID: 2461851
[TBL] [Abstract][Full Text] [Related]
5. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.
Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ
Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625
[TBL] [Abstract][Full Text] [Related]
6. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA.
Luque RM; Park S; Peng XD; Delgado E; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
J Mol Endocrinol; 2004 Apr; 32(2):437-48. PubMed ID: 15072550
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries.
Kimura N; Tomizawa S; Arai KN; Kimura N
Endocrinology; 1998 Apr; 139(4):1573-80. PubMed ID: 9528936
[TBL] [Abstract][Full Text] [Related]
8. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
9. 17 beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells.
Kimura N; Hayafuji C; Konagaya H; Takahashi K
Endocrinology; 1986 Sep; 119(3):1028-36. PubMed ID: 2874016
[TBL] [Abstract][Full Text] [Related]
10. Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin.
Goth MI; Lyons CE; Ellwood MR; Barrett JR; Thorner MO
Endocrinology; 1996 Jan; 137(1):274-80. PubMed ID: 8536623
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
12. Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2.
Reed DK; Korytko AI; Hipkin RW; Wehrenberg WB; Schonbrunn A; Cuttler L
Endocrinology; 1999 Oct; 140(10):4739-44. PubMed ID: 10499533
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
[TBL] [Abstract][Full Text] [Related]
14. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
16. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
[TBL] [Abstract][Full Text] [Related]
17. Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion.
Luque RM; Durán-Prado M; García-Navarro S; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
Endocrinology; 2006 Jun; 147(6):2902-8. PubMed ID: 16543371
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin inhibits basal and vasoactive intestinal peptide-stimulated hormone release by different mechanisms in GH pituitary cells.
Dorflinger LJ; Schonbrunn A
Endocrinology; 1983 Nov; 113(5):1551-8. PubMed ID: 6138245
[TBL] [Abstract][Full Text] [Related]
19. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
